FDA Has 18 Applications Remaining With User Fee Dates In 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Of the 18 total NDAs, there are six new molecular entities and one major biologic pending at FDA; the agency could surpass its 2003 NME tally if the six NMEs are approved. FDA remains behind in biologics with five approved thus far in 2004.
You may also be interested in...
New Molecular Entity Submissions Increase In FY 2004
FDA receives 28 NME filings in fiscal year 2004, marking the third year of growth. However, NME submissions have not climbed back up to the 1999-2001 level. BLA submissions spike in 2004 with 20 filings, up from eight the year before.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.